Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
362 GBX | -0.82% | -2.16% | +2.70% |
May. 22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
May. 22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
Financials (USD)
Sales 2024 * | 36.42M | Sales 2025 * | 46.63M | Capitalization | 486M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -45M | EV / Sales 2024 * | 9.25 x |
Net cash position 2024 * | 150M | Net cash position 2025 * | 120M | EV / Sales 2025 * | 7.86 x |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-11.1
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.86% |
Latest transcript on MaxCyte, Inc.
1 day | -3.01% | ||
1 week | -4.32% | ||
Current month | +20.00% | ||
1 month | +20.00% | ||
3 months | -2.34% | ||
6 months | -1.67% | ||
Current year | +0.43% |
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 362 | -0.82% | 12 580 |
24-05-24 | 365 | -0.54% | 1,623 |
24-05-23 | 367 | -2.13% | 13,975 |
24-05-22 | 375 | +1.35% | 35,319 |
24-05-21 | 370 | 0.00% | 39,584 |
Delayed Quote London S.E., May 28, 2024 at 08:14 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.43% | 487M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.97% | 65.19B | |
+15.38% | 53.02B | |
+3.64% | 50.28B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- MXCT Stock